TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TREACE MEDICAL CONCEPTS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.88+0.01 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $252.39M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.56 (−39.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TREACE MEDICAL CONCEPTS, INC. saw revenue fall 4.0% to $205.31M over the twelve months to Jun 30, 2026. Free cash flow was -$25.05M.
Revenue
$205.31M
-4.0% vs. a year earlier
Operating income
-$53.72M
TTM Q2 2026
Free cash flow
-$25.05M
TTM Q2 2026
EPS, diluted
-$0.93
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $252.39M
- P/E ratio
- –
- Price to sales
- 1.23
- Price to book
- 3.73
- Dividend yield
- –
- Free cash flow yield
- -9.92%
Fundamentals
- Revenue
- $205.31M
- Net income
- -$59.52M
- EPS, diluted
- -$0.93
- Free cash flow
- -$25.05M
- Book value per share
- $1.04
- Diluted shares
- 65M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$205.31M-4.0% YoY
Gross profit
$163.12M-4.7% YoY
Operating income
-$53.72M
Net income
-$59.52M
EPS, diluted
-$0.93
Free cash flow
-$25.05M
Reported periodTrailing twelve months